Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12253292 | 0.95 | LMNA (0.30) | LMNACYP2C9 | |
| SCHEMBL12253310 | 0.78 | TSHR (0.32) | — | |
| SCHEMBL15026091 | 0.77 | — | — | |
| SCHEMBL12253303 | 0.73 | TSHR (0.32) | — | |
| SCHEMBL2712241 | 0.69 | ALDH1A1 (0.31) | — | |
| SCHEMBL2712240 | 0.69 | ALDH1A1 (0.31) | — | |
| SCHEMBL7351253 | 0.69 | IDO1 (0.35) | — | |
| SCHEMBL3674669 | 0.69 | — | — | |
| SCHEMBL2714034 | 0.69 | ALDH1A1 (0.31) | — | |
| SCHEMBL12256236 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170224637-A1 | INTRANSAL DELIVERY OF CURCUMIN | DePuy Synthes Products, Inc. (US) | 2017-08-10 | — | — | US | disclosed |
| EP-2749552-A1 | Curcumin-resveratrol hybrids | Codman & Shurtleff, Inc. (US) | 2014-07-02 | — | — | EP | disclosed |
| US-20140163116-A1 | METHOD OF TREATING CANCER USING A CURCUMIN DERIVATIVE | DePuy Synthes Products, LLC (US) | 2014-06-12 | — | — | US | disclosed |
| US-20130150628-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A CURCUMIN DERIVATIVE | DIMAURO THOMAS M (US) | 2013-06-13 | — | — | US | disclosed |
| US-8350093-B2 | Methylated curcumin-resveratrol hybrid molecules for treating cancer | CODMAN & SHURTLEFF, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8288444-B2 | Iontophoretic delivery of curcumin and curcumin analogs for the treatment of Alzheimer's disease | CODMAN & SHURTLEFF, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20110257587-A1 | Iontophoretic Delivery of Curcumin and Curcumin Analogs for the Treatment of Alzheimers Disease | LILIENFELD SEAN | 2011-10-20 | — | — | US | disclosed |
| EP-2359820-A1 | Shunt delivery of curcumin for the treatment Alzneimer | Codman & Shurtleff, Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| US-7985776-B2 | charged curcuminoid such as bisdemethoxycurcumin, curcumin and glycinates, as well as hybrid compounds of bisdemethoxycurcumin and resveratrol, fisetin, or honokiol; bioavailability | CODMAN & SHURTLEFF, INC. (US) | 2011-07-26 | — | — | US | disclosed |
| US-20110130392-A1 | Method of Administering a Methylene Blue - Curcumin Analog for the Treatment of Alzheimer's Disease | DEPUY SPINE, LLC | 2011-06-02 | — | — | US | disclosed |
| US-7906643-B2 | Methylene blue-curcumin analog for the treatment of Alzheimer's Disease | CODMAN & SHURTLEFF, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20100292512-A1 | Methylated Curcumin-Resveratrol Hybrid Molecules for Treating Cancer | DEPUY SPINE, LLC | 2010-11-18 | — | — | US | disclosed |
| US-20100190978-A1 | METHYLENE BLUE - CURCUMIN ANALOG FOR THE TREATMENT OF ALZHEIMER'S DISEASE | CODMAN & SHURTLEFF, INC. | 2010-07-29 | — | — | US | disclosed |
| US-7745670-B2 | Curcumin-Resveratrol hybrid molecule | CODMAN & SHURTLEFF, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7723515-B1 | Methylene blue—curcumin analog for the treatment of alzheimer's disease | CODMAN & SHURTLEFF, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090326275-A1 | USE OF NITROGEN-CONTAINING CURCUMIN ANALOGS FOR THE TREATMENT OF ALZHEIMERS DISEASE | DEPUY SPINE, LLC | 2009-12-31 | — | — | US | disclosed |
| US-20090325963-A1 | Iontophoretic Delivery of Curcumin and Curcumin Analogs for the Treatment of Alzheimer's Disease | CODMAN & SHURTLEFF, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090087385-A1 | Intranasally administering curcumin in a bolus of helium gas to treat alzheimers disease | CODMAN & SHURTLEFF, INC. | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292512-A1 | Methylated Curcumin-Resveratrol Hybrid Molecules for Treating Cancer | DNMT1, MECP2, BMI1 | LMNA 2814/4885CYP2C9 3451/4885 |
| US-20100190978-A1 | METHYLENE BLUE - CURCUMIN ANALOG FOR THE TREATMENT OF ALZHEIMER'S DISEASE | APP, PSEN2, MAPT | LMNA 2520/4885CYP2C9 1998/4885 |
| US-20090326275-A1 | USE OF NITROGEN-CONTAINING CURCUMIN ANALOGS FOR THE TREATMENT OF ALZHEIMERS DISEASE | SLC1A3, SLC1A1, SLC1A2 | LMNA 3013/4885CYP2C9 2990/4885 |
| US-20110130392-A1 | Method of Administering a Methylene Blue - Curcumin Analog for the Treatment of Alzheimer's Disease | APP, PSEN2, MAPT | LMNA 1584/4885CYP2C9 1204/4885 |
| US-20130150628-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A CURCUMIN DERIVATIVE | CPT1A, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ABCB1 | LMNA 2741/4885CYP2C9 18/4885 |
| US-20140163116-A1 | METHOD OF TREATING CANCER USING A CURCUMIN DERIVATIVE | HDAC5, HDAC6, CPT1A | LMNA 2133/4885CYP2C9 546/4885 |
| US-20170224637-A1 | INTRANSAL DELIVERY OF CURCUMIN | FABP7, FABP2, NDUFB5 | LMNA 2319/4885CYP2C9 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.